NCT03249376: A trial that was reported late by Intra-Cellular Therapies, Inc.
This trial has reported, although it was 50 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03249376 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 27, 2017 |
| Completion date | March 1, 2019 |
| Required reporting date | March 1, 2022, midnight |
| Actual reporting date | April 20, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 50 |